1. In Vivo
  2. >>Innovation

Treat, Prevent, Restore: Sensorion’s Approach To Hearing Loss

French Biotech Is Developing Small Molecules And Gene Therapies

 
• By Chloe Kent

Hearing loss lacks pharmacological treatment options, with patients instead relying on medical devices or going untreated. In Vivo spoke to French biotech Sensorion, which is targeting a number of hearing loss indications with small-molecule drugs and gene therapies.

Adult woman and young girl conversing in sign language at a playground
• Source: Shutterstock

A lack of approved pharmacological therapies for hearing loss, whether acquired or congenital, is a gap in the market that a number of biotechs and big pharmaceutical firms are looking to plug. While medical devices such as hearing aids or cochlear implants can be a boon for patients who are deaf or hard of hearing, a lack of drug treatment options represents a significant unmet medical need.

“The biological approaches a patient needs are very different” depending on whether their hearing loss can be treated or prevented, or whether their hearing can be restored,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By Jo Shorthouse

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.